Eastern Virginia Medical School receives $100 million grant from USAID for microbicide research

Eastern Virginia Medical School on Monday announced that it has received a $100 million grant from USAID for microbicide research through its CONRAD program, the Virginian-Pilot reports.

According to EVMS, the grant will help its more than 20 years of research into microbicides. "It's an extraordinary grant," Gustavo Doncel, pre-clinical director for CONRAD, said, adding, "Our main goal with the grant is to improve reproductive health in developing countries." According to Doncel, CONRAD researchers are focusing on several microbicide candidates(Simpson, Virginian-Pilot, 9/8).

The funding will be distributed at $20 million annually for five years to help pay for microbicide trials, according to Reuters. Two candidates that CONRAD is researching are a microbicide that uses the antiretroviral drug tenofovir and another experimental candidate called UC781(Fox, Reuters, 9/8).

CONRAD also is researching combination products that not only would provide protection against HIV but also would prevent other sexually transmitted infections and unplanned pregnancies. In addition, researchers aim to develop products that will be effective over longer periods of time, rather than applying the microbicide before sex, Doncel said. He added that he expects it will take another 10 years before a microbicide is available on the market. CONRAD Executive Director Henry Gabelnick said that the program has received about $400 million in grants for its work (Virginian-Pilot, 9/8).

According to a USAID spokesperson, the agency receives about $40 million annually from Congress for microbicide development and provides funding to several programs, including the Population Council and the International Partnership for Microbicides (Reuters, 9/8).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New long COVID index highlights five symptom subtypes